Paul Andrew Gendron Acquires 5,000 Shares of InfuSystem (NYSE:INFU) Stock

Posted by Francis Steltz on May 14th, 2026

InfuSystem Holdings, Inc. (NYSE:INFU – Get Free Report) Director Paul Andrew Gendron purchased 5,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was purchased at an average cost of $8.88 per share, with a total value of $44,400.00. Following the purchase, the director owned 70,000 shares in the company, valued at approximately $621,600. This trade represents a 7.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

InfuSystem Stock Performance

InfuSystem stock opened at $8.21 on Thursday. The firm has a 50 day simple moving average of $9.64 and a 200-day simple moving average of $9.19. InfuSystem Holdings, Inc. has a 1-year low of $5.08 and a 1-year high of $11.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The stock has a market cap of $165.79 million, a price-to-earnings ratio of 136.86 and a beta of 1.49.

Institutional Investors Weigh In On InfuSystem

A number of hedge funds and other institutional investors have recently modified their holdings of INFU. Quarry LP acquired a new stake in shares of InfuSystem in the 4th quarter valued at $31,000. Raymond James Financial Inc. acquired a new stake in shares of InfuSystem in the 2nd quarter valued at $33,000. Virtu Financial LLC acquired a new stake in shares of InfuSystem in the 4th quarter valued at $90,000. LPL Financial LLC acquired a new stake in shares of InfuSystem in the 4th quarter valued at $92,000. Finally, GK Wealth Management LLC acquired a new stake in shares of InfuSystem in the 4th quarter valued at $95,000. 71.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Roth Mkm reiterated a “buy” rating and set a $15.00 target price (up from $14.00) on shares of InfuSystem in a report on Tuesday, February 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, InfuSystem presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

View Our Latest Research Report on INFU

InfuSystem Company Profile

(Get Free Report)

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem’s offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.